ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: TH-OR129

Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Meta-Analysis

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical


  • Gonzalez Suarez, Maria Lourdes, University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Thongprayoon, Charat, Bassett Medical Center, Cooperstown, New York, United States
  • Mao, Michael A., Mayo Clinic, Rochester, Minnesota, United States
  • Cheungpasitporn, Wisit, University of Mississippi Medical Center, Jackson, Mississippi, United States

Kidney transplantation in patients with atypical hemolytic uremic syndrome (aHUS) is frequently complicated by recurrence of aHUS, often resulting in thrombotic microangiopathy (TMA) in the renal allograft and graft loss. We aimed to assess the efficacy of eculizumab in the prevention and treatment of aHUS recurrence after kidney transplantation.


Databases (MEDLINE, EMBASE and Cochrane Database) were searched through March 2018. Studies that reported outcomes of adult kidney transplant recipients with aHUS treated with eculizumab were included. Effect estimates from the individual studies were extracted and combined using random-effect, generic inverse variance method of DerSimonian and Laird. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018089438).


Fourteen studies (11 cohort studies and 3 case series) that consisted of 167 adult kidney transplant patients with aHUS who received eculizumab for prevention and/or treatment of post-transplant aHUS recurrence were included into the analysis. Among patients who received prophylactic eculizumab, the pooled estimated rates of aHUS recurrence and allograft loss due to TMA were 7.9% (95%CI: 3.4%-17.5%, I2 =0%) and 6.6% (95%CI: 2.8%-15.1%, I2 =0%), respectively. Among patients who received eculizumab for treatment of post-transplant aHUS recurrence, the pooled estimated rates of allograft loss due to TMA was 24.1% (95%CI: 14.8%-36.7%, I2 =10%). When the meta-analysis was restricted only to cohort studies with data on genetic mutations associated with aHUS, the pooled estimated incidence of allograft loss due to TMA after eculizumab therapy was 22.6% (95%CI: 13.2%-36.0%, I2 =10%). We found no publication bias as assessed by funnel plots and Egger’s regression asymmetry test (P values >0.05 for all analyses).


The use of eculizumab for prevention of aHUS recurrence after kidney transplantation seems to be more effective than treatment with eculizumab after post-transplant aHUS recurrence. Our findings suggest that kidney transplant patients with history of aHUS may have better allograft survival when prophylactic eculizumab is started at the time of kidney transplantation. Randomized control trials are important to further investigate this.